VYNE Therapeutics VYNE Stock
VYNE Therapeutics Price Chart
VYNE Therapeutics VYNE Financial and Trading Overview
| VYNE Therapeutics stock price | 2.77 USD |
| Previous Close | 5.2 USD |
| Open | 5.19 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1100 |
| Day's Range | 4.61 - 5.19 USD |
| 52 Week Range | 2 - 9.72 USD |
| Volume | 27.58K USD |
| Avg. Volume | 727.08K USD |
| Market Cap | 15.59M USD |
| Beta (5Y Monthly) | 1.510946 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.72 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.33 USD |
VYNE Valuation Measures
| Enterprise Value | -13202365 USD |
| Trailing P/E | N/A |
| Forward P/E | -2.2592418 |
| PEG Ratio (5 yr expected) | -0.01 |
| Price/Sales (ttm) | 39.181385 |
| Price/Book (mrq) | 0.5899753 |
| Enterprise Value/Revenue | -33.172 |
| Enterprise Value/EBITDA | 0.42 |
Trading Information
VYNE Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.510946 |
| 52-Week Change | -47.96% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.72 USD |
| 52 Week Low | 2 USD |
| 50-Day Moving Average | 5.55 USD |
| 200-Day Moving Average | 4.35 USD |
VYNE Share Statistics
| Avg. Volume (3 month) | 727.08K USD |
| Avg. Daily Volume (10-Days) | 22.98K USD |
| Shares Outstanding | 3.27M |
| Float | 3.14M |
| Short Ratio | 0.66 |
| % Held by Insiders | 1.54% |
| % Held by Institutions | 13.42% |
| Shares Short | 65K |
| Short % of Float | 2.00% |
| Short % of Shares Outstanding | 1.99% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:18 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -7909.29% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.51% |
| Return on Equity (ttm) | -75.12% |
Income Statement
| Revenue (ttm) | 398K USD |
| Revenue Per Share (ttm) | 0.12 USD |
| Quarterly Revenue Growth (yoy) | -44.39% |
| Gross Profit (ttm) | 477K USD |
| EBITDA | -31433000 USD |
| Net Income Avi to Common (ttm) | -30863000 USD |
| Diluted EPS (ttm) | -9.51 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.21M USD |
| Total Cash Per Share (mrq) | 9.24 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.392 |
| Book Value Per Share (mrq) | 8.08 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25639000 USD |
| Levered Free Cash Flow (ttm) | -8988375 USD |
Profile of VYNE Therapeutics
| Country | United States |
| State | NJ |
| City | Bridgewater |
| Address | 685 Route 202/206 N |
| ZIP | 08807 |
| Phone | 800 775 7936 |
| Website | https://www.vynetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Q&A For VYNE Therapeutics Stock
What is a current VYNE stock price?
VYNE Therapeutics VYNE stock price today per share is 2.77 USD.
How to purchase VYNE Therapeutics stock?
You can buy VYNE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for VYNE Therapeutics?
The stock symbol or ticker of VYNE Therapeutics is VYNE.
Which industry does the VYNE Therapeutics company belong to?
The VYNE Therapeutics industry is Biotechnology.
How many shares does VYNE Therapeutics have in circulation?
The max supply of VYNE Therapeutics shares is 14.1M.
What is VYNE Therapeutics Price to Earnings Ratio (PE Ratio)?
VYNE Therapeutics PE Ratio is now.
What was VYNE Therapeutics earnings per share over the trailing 12 months (TTM)?
VYNE Therapeutics EPS is -2.72 USD over the trailing 12 months.
Which sector does the VYNE Therapeutics company belong to?
The VYNE Therapeutics sector is Healthcare.
VYNE Therapeutics VYNE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}